Holen Sie sich die Stockscreener-App
56.20
11.62%
5.85
Handel nachbörslich:
55.55
-0.65
-1.16%
Schlusskurs vom Vortag:
$50.35
Offen:
$50.4
24-Stunden-Volumen:
37.02M
Relative Volume:
1.06
Marktkapitalisierung:
$12.23B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
81.45
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
+8.58%
1M Leistung:
+24.61%
6M Leistung:
+78.47%
1J Leistung:
+244.57%
1-Tages-Spanne:
$50.27
$56.31
1-Wochen-Bereich:
$48.69
$56.52
52-Wochen-Spanne:
$15.73
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
56.20 | 11.38B | 1.78B | 164.40M | 236.51M | 0.69 |
|
PG
Procter Gamble Co
|
157.32 | 375.25B | 84.28B | 16.07B | 14.05B | 6.51 |
|
UL
Unilever Plc Adr
|
61.46 | 153.05B | 64.99B | 6.71B | 6.53B | 2.4495 |
|
CL
Colgate Palmolive Co
|
81.53 | 66.45B | 20.00B | 3.05B | 3.37B | 3.56 |
|
KMB
Kimberly Clark Corp
|
125.51 | 41.67B | 18.88B | 2.38B | 2.10B | 7.26 |
|
KVUE
Kenvue Inc
|
18.10 | 35.20B | 15.14B | 1.42B | 1.63B | 0.74 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Health: Bumpy Ride Will End - Seeking Alpha
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs - Yahoo Finance
Hims & Hers Is An Interesting Story, But Not The One I Signed Up ForDowngrade - Seeking Alpha
FDA Hims And Hers Misleading Claims Warning - Effingham Radio
Lake Hills Wealth Management LLC Makes New Investment in Hims & Hers Health, Inc. $HIMS - MarketBeat
Rep. Lisa C. McClain Buys Hims & Hers Health, Inc. (NYSE:HIMS) Stock - MarketBeat
Hims & Hers Health (NYSE:HIMS) Stock Price Down 8.4%What's Next? - MarketBeat
Why Novo Nordisk Stock Popped Today - The Motley Fool
FDA Cracks Down on Hims, Other Telehealth Companies Over Drug Ads - WFMZ.com
In a first, FDA calls out Hims and other telehealth companies for GLP-1 advertising - Endpoints News
Should Investors Rethink Hims & Hers After FDA Flags Super Bowl Ad and Shares Double in 2025? - Yahoo Finance
Hims & Hers Health, Inc. $HIMS Stock Position Raised by Fiduciary Alliance LLC - MarketBeat
Strs Ohio Buys New Shares in Hims & Hers Health, Inc. $HIMS - MarketBeat
Hims & Hers Health, Inc. $HIMS Shares Sold by Belpointe Asset Management LLC - MarketBeat
Range Financial Group LLC Invests $996,000 in Hims & Hers Health, Inc. $HIMS - MarketBeat
FDA accuses Hims & Hers of violations for ‘false or misleading’claims about weight-loss drugs - Investorsobserver
Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims - Red Lake Nation News
FDA takes aim at Hims & Hers and other sellers of unofficial weight loss drugs - Anchorage Daily News
FDA takes aim at Hims & Hers, weight loss drugs in new advertising blitz - The Daily Citizen
FDA targets Hims & Hers, posts more than 100 letters to drugmakers - WTVC
Lilly, Novo, Hims Get FDA Warnings About Misleading Drug Communications - PharmTech
Why The FDA — And Investors — Just Slammed Hims Stock - Investor's Business Daily
FDA warns Hims & Hers and other weight loss drugmakers to remove 'false and misleading' advertising - Fortune
Hims falls after FDA posts warning letter - Sherwood News
FDA’s pharma ad crackdown targets Hims & Hers, weight loss drugs - Dallas News
Hims & Hers Health (HIMS) Stock Trades Down, Here Is Why - TradingView
Hims & Hers shares drop 6% after FDA warning on semaglutide marketing claims - CryptoRank
Gold's record high, Rocket Lab equity offering, FDA warns Hims - Yahoo Finance
FDA takes aim at Hims and other telehealth services in drug advertising blitz - Daily Breeze
Promising Medical Stocks To Add to Your WatchlistSeptember 16th - MarketBeat
BigBear.ai, Tesla, Hims & Hers, Rocket Lab, Warner Bros Discovery: Stocks Making The Biggest Moves Today - Stocktwits
What's Going On With Hims & Hers Health Stock On Tuesday?Hims & Hers Health (NYSE:HIMS) - Benzinga
Hims & Hers Health, Inc. (HIMS): A Bull Case Theory - MSN
Market Dips As Fed Meets And Companies Make Headlines - Finimize
US FDA warns Hims & Hers over misleading claims on diabetes, weight-loss drugs - Reuters
HIMS Receives FDA Warning Over Misleading Drug Claims - GuruFocus
Huge News for Hims & Hers Stock - The Globe and Mail
Hims & Hers falls 8% as FDA issues warning letter over compounded weight loss drug - Seeking Alpha
Hims & Hers stock falls after FDA warning over semaglutide claims By Investing.com - Investing.com South Africa
Hims & Hers stock falls after FDA warning over semaglutide claims - Investing.com
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hims Hers Health Inc-Aktie (HIMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chi Michael | Chief Commercial Officer |
Sep 15 '25 |
Sale |
56.00 |
4,150 |
232,400 |
278,654 |
| Dudum Andrew | Chief Executive Officer |
Sep 16 '25 |
Option Exercise |
2.43 |
125,335 |
304,564 |
268,759 |
| Dudum Andrew | Chief Executive Officer |
Sep 16 '25 |
Sale |
53.48 |
128,127 |
6,852,300 |
160,425 |
| Dudum Andrew | Chief Executive Officer |
Sep 16 '25 |
Sale |
53.27 |
47,534 |
2,532,325 |
95,058 |
| Okupe Oluyemi | Chief Financial Officer |
Sep 15 '25 |
Option Exercise |
5.01 |
110,000 |
551,100 |
273,984 |
| Okupe Oluyemi | Chief Financial Officer |
Sep 15 '25 |
Sale |
55.35 |
145,000 |
8,026,076 |
128,984 |
1.02%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):